20231407 - Correa Zelia
-
Investigator:
Zelia Correa
Email
Coordinator:
IRB: 20231407
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Eye and Orbit
Sponsor: Aura Biosciences Inc
Enrolling Sites:
ABLEH
Aventura
Deerfield
Sylvester
UMHTitle: A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma
Eligibility Criteria - NCT06007690 *This information has been extracted from " www.clinicaltrials.gov"
20231156 - Crystal Jessica
-
Investigator:
Jessica Crystal
Email
Coordinator:
IRB: 20231156
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Melanoma, skin
Sponsor: SWOG
Enrolling Sites:
Aventura
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
SylvesterTitle: MELANOMA MARGINS TRIAL (MELMART): A PHASE III, MULTI-CENTRE, MULTI-NATIONAL RANDOMISED CONTROL TRIAL INVESTIGATING 1CM V 2CM WIDE EXCISION MARGINS FOR PRIMARY CUTANEOUS MELANOMA
Eligibility Criteria - NCT03860883 *This information has been extracted from " www.clinicaltrials.gov"
ECOG EA6141 - Feun, Lynn
-
Investigator:
Lynn Feun
Email
Coordinator: Milton Ortega
+1 (305) 2432086
IRB: 20150909
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Melanoma, skin
Sponsor: ECOG
Enrolling Sites:
Aventura
Deerfield
Plantation
SylvesterTitle: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Eligibility Criteria - NCT02339571 *This information has been extracted from " www.clinicaltrials.gov"
20201288 - Feun Lynn
-
Investigator:
Lynn Feun
Email
Coordinator:
IRB: 20201288
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Multiple
Sponsor: ECOG
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)
Eligibility Criteria - NCT04462406 *This information has been extracted from " www.clinicaltrials.gov"
20231324 - Feun Lynn
-
Investigator:
Lynn Feun
Email
Coordinator:
IRB: 20231324
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Colon
Sponsor: SCCC
Enrolling Sites:
Aventura
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
Sylvester
UMHTitle: Phase 2, Single Arm Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
Eligibility Criteria - NCT06627244 *This information has been extracted from " www.clinicaltrials.gov"
20211228 - Hernandez Aya Leonel
-
Investigator:
Leonel Hernandez Aya
Email
Coordinator:
IRB: 20211228
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Melanoma, skin
Sponsor: Syntrix Pharmaceuticals
Enrolling Sites:
Sylvester
Title: A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Eligibility Criteria - NCT03161431 *This information has been extracted from " www.clinicaltrials.gov"
20220869 - Hernandez Aya Leonel
-
Investigator:
Leonel Hernandez Aya
Email
Coordinator:
IRB: 20220869
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Melanoma, skin
Sponsor: ETCTN
Enrolling Sites:
Aventura
Deerfield
Gables
Plantation
SylvesterTitle: Phase 1/2 Study of an EZH2 inhibitor (tazemetostat) in combination with dual BRAF/MEK inhibition in patients with BRAF- mutated metastatic melanoma who progressed on prior BRAF/MEK inhibitor therapy
Eligibility Criteria - NCT04557956 *This information has been extracted from " www.clinicaltrials.gov"
20230131 - Hernandez Aya Leonel
-
Investigator:
Leonel Hernandez Aya
Email
Coordinator:
IRB: 20230131
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Multiple
Sponsor: Alliance
Enrolling Sites:
Aventura
Deerfield
Gables
Plantation
SylvesterTitle: A Randomized Phase II Trial of Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Mucosal Melanoma
Eligibility Criteria - NCT05111574 *This information has been extracted from " www.clinicaltrials.gov"
20230532 - Hernandez Aya Leonel
-
Investigator:
Leonel Hernandez Aya
Email
Coordinator:
IRB: 20230532
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Multiple
Sponsor: Asher Biotherapeutics
Enrolling Sites:
Aventura
Deerfield
Gables
Plantation
Sylvester
UMHTitle: An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
Eligibility Criteria - NCT05653882 *This information has been extracted from " www.clinicaltrials.gov"
20230072 - Kirsner Robert
-
Investigator:
Robert Kirsner
Email
Coordinator:
IRB: 20230072
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Multiple
Sponsor: Hoth Therapeutics
Enrolling Sites:
Sylvester
Title: A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors
Eligibility Criteria - NCT05639933 *This information has been extracted from " www.clinicaltrials.gov"
20221372 - Lutzky Jose
-
Investigator:
Jose Lutzky
Email
Coordinator:
IRB: 20221372
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Melanoma, skin
Sponsor: IB
Enrolling Sites:
ABLEH
Aventura
Deerfield
Gables
Kendall
Plantation
Sylvester
UMHTitle: A Phase 1/2, open-label study of PD-1 knockout tumor-infiltrating lymphocytes (IOV-4001) in participants with unresectable or metastatic melanoma or Stage III or IV non-small-cell lung cancer
Eligibility Criteria - NCT05361174 *This information has been extracted from " www.clinicaltrials.gov"
20230966 - Lutzky Jose
-
Investigator:
Jose Lutzky
Email
Coordinator:
IRB: 20230966
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Eye and Orbit
Sponsor: Ideaya Biosciences
Enrolling Sites:
Aventura
Deerfield
Gables
Plantation
SylvesterTitle: IDE196 (Darovasertib) In Combination With Crizotinib Versus Investigators Choice Of Treatment As First-Line Therapy In HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)
Eligibility Criteria - NCT05987332 *This information has been extracted from " www.clinicaltrials.gov"
20231406 - Lutzky Jose
-
Investigator:
Jose Lutzky
Email
Coordinator:
IRB: 20231406
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Kidney
Sponsor: ETCTN
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancer
Eligibility Criteria - NCT05896839 *This information has been extracted from " www.clinicaltrials.gov"
20231430 - Lutzky Jose
-
Investigator:
Jose Lutzky
Email
Coordinator:
IRB: 20231430
SDG: Cutaneous and Ocular Malignancies
Disease Site(s): Other Skin
Sponsor: ETCTN
Enrolling Sites:
Aventura
Deerfield
Gables
Kendall
Plantation
SylvesterTitle: A Randomized Phase 2 Study of ATR inhibition in advanced PD-(L)1-refractory Merkel cell carcinoma: The MATRiX Trial
Eligibility Criteria - NCT05947500 *This information has been extracted from " www.clinicaltrials.gov"